We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

THE BINDING SITE

Engages in the research, development, manufacture, and distribution of immunodiagnostic assays, as wel as specialized... read more Featured Products: More products

Download Mobile App




Mass Spectrometry Versus Immunofixation to Monitor Multiple Myeloma Treatment

By LabMedica International staff writers
Posted on 30 Jun 2022

The monoclonal protein (M-protein), secreted by the tumor plasma cells in patients with multiple myeloma (MM), has long been used as a biomarker to evaluate treatment response. More...

Treatment monitoring in MM is mainly based on the identification and quantification of the M-protein by electrophoresis and/or immunofixation (IFE) in serum and urine samples.

Although the clinical value of these methods has been broadly demonstrated, the current use of highly active therapies has significantly increased the proportion of patients in whom the M-protein becomes undetectable by IFE during and after treatment. There is an urgent need to adjust the sensitivity of the techniques used for response assessment to the current treatment efficacy.

A large team of Hematologists at the Centro de Investigación Biomédica en Red de Cáncer (CIBERONC, Madrid, Spain) and their colleagues included the first 223 out of the 458 newly diagnosed transplant-eligible patients with MM enrolled the PETHEMA/GEM2012MENOS65 trial. This open-label, phase 3 trial encompassed the administration of six induction cycles of bortezomib, lenalidomide, and dexamethasone and autologous stem-cell transplantation (ASCT) followed by two consolidation cycles of bortezomib, lenalidomide, and dexamethasone.

The presence of an M-protein in serum was assessed in parallel by IFE on the Hydrasys 2 instrument using the Hydragel 9 kit (Sebia Inc, Norcross, GA. USA) and by Mass Spectrometry (MS) using the EXENT system (The Binding Site; Birmingham, UK). Pooled normal serum was used as a negative control. The EXENT-iP500 liquid handler purified the immunoglobulins through paramagnetic beads coated with polyclonal sheep antibodies specific for human immunoglobulins. Then, analysis with the EXENT-iX500 matrix-assisted laser desorption/ionization-time of flight device was carried out, and mass spectra from 5,000 to 32,000 mass-to-charge ratio were collected.

The investigators reported that at baseline, the isotypes identified with both methods fully matched in 82.1% of samples. In the rest but for two cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in more than 80% of cases, being most discordances due to EXENT&FLC-MS positive, but IFE negative cases. After consolidation, IFE was not able to discriminate two cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so. Furthermore, among IFE negative patients, EXENT&FLC-MS identified two groups with significantly different median PFS.

The authors concluded that compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients’ outcome. The study was published on May 31, 2022 in the journal Blood Advances.

Related Links:
Centro de Investigación Biomédica en Red de Cáncer
Sebia
The Binding Site


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.